These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 38759335

  • 1. Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm.
    Paolieri F, Sammarco E, Ferrari M, Salfi A, Bonato A, Serafin D, Coccia N, Manfredi F, Zatteri L, Dima G, Carli C, Di Vita R, Oliveri M, Doni L, Galli L, Sisani M, Catalano M, Roviello G, Bloise F.
    Clin Genitourin Cancer; 2024 Aug; 22(4):102096. PubMed ID: 38759335
    [Abstract] [Full Text] [Related]

  • 2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 3. Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy.
    Ye SJ, Huang RD, Fei X, Tao ZL, Liu WH, Ma Q.
    Postgrad Med J; 2024 Sep 22; 100(1188):703-708. PubMed ID: 38767468
    [Abstract] [Full Text] [Related]

  • 4. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
    Leith A, Ribbands A, Kim J, Clayton E, Gillespie-Akar L, Yang L, Ghate SR.
    BMC Urol; 2022 Mar 11; 22(1):33. PubMed ID: 35277153
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May 11; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 7. Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies.
    Sciarra A, Busetto GM, Salciccia S, Del Giudice F, Maggi M, Crocetto F, Ferro M, De Berardinis E, Scarpa RM, Porpiglia F, Carmignani L, Damiano R, Artibani W, Carrieri G.
    Front Endocrinol (Lausanne); 2021 May 11; 12():695170. PubMed ID: 34194398
    [Abstract] [Full Text] [Related]

  • 8. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ.
    Prostate; 2018 Sep 11; 78(12):889-895. PubMed ID: 29707790
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.
    Eur Urol; 2017 Apr 11; 71(4):630-642. PubMed ID: 27591931
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
    Park K, Kim JY, Park I, Shin SH, Lee HJ, Lee JL.
    Yonsei Med J; 2023 Feb 11; 64(2):86-93. PubMed ID: 36719015
    [Abstract] [Full Text] [Related]

  • 13. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
    Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Mori K, Sano T, Otsuka T, Iwamoto Y, Enei Y, Nakazono M, Sakanaka K, Iwatani K, Matsukawa A, Atsuta M, Nishikawa H, Tsuzuki S, Miki J, Habuchi T, Ohyama C, Shariat SF, Egawa S.
    World J Urol; 2023 Aug 11; 41(8):2051-2062. PubMed ID: 35596809
    [Abstract] [Full Text] [Related]

  • 14. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N.
    Prostate; 2024 Jun 11; 84(9):888-892. PubMed ID: 38561317
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A.
    J Clin Oncol; 2019 Nov 10; 37(32):2974-2986. PubMed ID: 31329516
    [Abstract] [Full Text] [Related]

  • 20. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF, Kimura T.
    Prostate; 2023 May 10; 83(6):563-571. PubMed ID: 36661102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.